Back to School: How biopharma can reboot drug development. Access exclusive analysis here
BBG said that the combination of marimastat and Eli Lilly’s Gemzar gemcitabine failed to show
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury